To download the latest issue
Aug 21st, 2012
Fluidigm announces exercise of underwriters’ over-allotment option and closing of $60 million public offering of common stock
Fluidigm Corporation a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries announces that it has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
The shares include 549,000 shares of common stock sold pursuant to the over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by Fluidigm, will be approximately $56.1 million.
More MEDTECH news